Physician profile
James Boris
NPI 1902477474
$409.91
in general payments reported to CMS, 2019-2025
10 companies · $76.93 in 2025
The $76.93 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.19 · 2023: $18.30 · 2024: $253 · 2025: $76.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78.62 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $78.53 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $58.41 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Pfizer INC. | $36.33 | 2024 | |
| La Jolla Pharmaceutical Company | $35.31 | 2024 | Giapreza, Xacduro |
| E.R. Squibb & Sons, L.L.C. | $30.07 | 2024-2025 | Camzyos, Eliquis |
| Vapotherm INC | $25.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.15 | 2024 | Jardiance |
| Ceribell, INC. | $23.06 | 2025 | Pocket Eeg Device |
| Tetraphase Pharmaceuticals, INC. | $21.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.